Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Oncology (Williston Park, N.Y.)|February 24, 2001
Irinotecan in the management of patients with pancreatic cancerM R Green, M Harper, A Safa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLCC M Rocha Lima, N A Rizvi, C Zhang, et al.
Seminars in Oncology|December 10, 1999
Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancerC M Rocha Lima, J R Eckardt, S S Leong, et al.
British Journal of Cancer|June 2, 2011
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapyC R Garrett, L L Siu, A El-Khoueiry, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2012
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancerH L Kindler, D A Richards, L E Garbo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2013
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancerB M Wolpin, E M O'Reilly, Y J Ko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trialJ M Weiss, T Csoszi, M Maglakelidze, et al.
Pageof 2